Israeli drug companies Clal Biotech Industries and BiolineRX sign an agreement for developing and commercializing Clal’s BL-8040, a drug designed for treating acute leukemia and other types of blood cancer. The American FDA has approved the companies’ investigational new drug application.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments